Shots:

• Protagonist to receive ~ $900M as development & sales milestones along with $80M already received under the original agreement with royalty rates remain unchanged. Janssen will get right to continue research on IL-23 receptor antagonists developed under a collaboration for 3yrs. following the closing of the amended agreement
• Janssen will lead all future studies beyond the currently ongoing studies with PTG-200- PN-232 and PN-235 and will be solely financially responsible for any studies. The company will deploy its capabilities & experience for further development of these assets
• PTG-200 is currently in P-II study for CD while PN-232 and PN-235 are currently in P-I clinical development

Ref: PR Newswire | Image: Janssen